Wellgistics Health
Tampa, Florida, United States · Biotechnology, Health Care, Information Technology
Wellgistics Health, Inc. is a leader in next-generation pharmaceutical distribution, digital prescription routing, and AI-powered hub fulfillment. The firm focuses on advancing healthcare technology and solutions for independent pharmacists. With a recent management upgrade, Wellgistics aims to become a force in blockchain-enabled medication tracking. They are enhancing their capabilities to meet
Key facts
- Headquarters
- Tampa, Florida, United States
- Employees
- 51
- Industries
- Biotechnology, Health Care, Information Technology
- Status
- Public (MEDS)
- Website
- wellgisticshealth.com
- Company page
Recent activity at Wellgistics Health
- : SEC 8-K (8.01): The filing reports an important event concerning the compliance status of DataMeds AI, Inc. with Nasdaq Listing Rule 5550(b)(1). On October 19, 2026, the Company received written notice from Nasdaq's Listing Qualifications Department confirming that it has regained compliance with the minimum stockholders' equity requirement after previously receiving a deficiency letter on April 13, 2026. This event is significant as it impacts the Company's listing status on the Nasdaq Capital Market, which is critical for its continued market presence and investor confidence. The deficiency letter had indicated that the Company did not meet the minimum requirement due to negative stockholders' equity of $(12,447,801). The timely regain of compliance could improve the Company's market positioning and financial stability going forward.
- : DataMeds AI Enters Intellectual Property License Agreement with REBOOT Health AI
- : SEC 8-K (8.01): As of October 13, 2026, DataMEDS AI, Inc. confirms its stockholders’ equity has increased to over $2,500,000 due to the conclusion of significant legal settlements and licensing agreements. On September 11, 2026, the Company entered into a settlement agreement with Brian Norton and several other parties, resulting in a $450,000 payment to extinguish liabilities and repurchase 364,099 shares of common stock, alleviating approximately $19 million in liabilities. Additionally, on October 13, 2026, DataMEDS licensed a care management platform from REBOOT Health AI, Inc., issuing 666,667 shares of common stock as part of this agreement, effectively integrating new capabilities into its business model.
- : SEC 8-K (1.01): On October 13, 2026, DataMeds AI, Inc. entered into an Intellectual Property License and Product and Services Agreement with REBOOT Health AI, Inc. This agreement grants DataMeds an exclusive license to REBOOT's Licensed Patents and the REBOOT Health AI Platform for use in their GLP-1 weight management business. As part of the agreement, DataMeds will issue 666,667 shares of its common stock to REBOOT, with additional shares required if the market value of those shares falls below $2,000,000 after 180 days. DataMeds is also obligated to pay REBOOT $50,000 upfront for reconfiguration costs towards the DataMeds Platform, estimated to total at least $100,000. The agreement is effective perpetually, pending the validity of the Licensed Patents.
- : SEC 8-K (8.01):
- : SEC 8-K (1.01):
- : SEC 8-K (8.01):
- : SEC 8-K (1.01): DataMEDS AI, Inc. entered into an Amended and Restated Letter of Intent (LOI) on July 29, 2026, to acquire certain intellectual property assets related to Quality of Life Peace of Mind from EOS Technology Holdings, Inc. and Scilex Holding Company. The transaction also includes expanding the PharmacyChain license with Datavault AI Inc. and acquiring a controlling interest in Tollo Health, LLC through an exchange of membership interests with HealthBridge Advisors, LLC. Upon finalization, the agreement anticipates that the new stakeholders will own approximately 84.6% of the Company’s common stock. The execution of this LOI is part of a strategy to enhance the company’s offerings and financial standing as it will also address existing liabilities through financing transactions prior to closing.
- : SEC 8-K (8.01): On July 27, 2026, DataMeds AI, Inc. issued a press release updating the record date for the distribution of the Dream Bowl 2026 Meme Coin to August 7, 2026. This event signals a significant organizational decision regarding the issuance of a new cryptocurrency, potentially impacting stakeholders and investors interested in the upcoming distribution. The updated record date provides clarity for shareholders on eligibility for receiving the coin. The press release is attached as Exhibit 99.1, serving as an official communication regarding this noteworthy event.
- : SEC 8-K (8.01): On July 21, 2026, Wellgistics Health, Inc. announced a Name Change and Symbol Change through a press release, thereby indicating a significant rebranding or corporate identity modification. This change may reflect strategic directions for the company or a shift in its market positioning. The related Certificate of Amendment to the Amended and Restated Certificate of Incorporation was dated July 20, 2026, highlighting an official update in the company’s registration records. Such rebranding could have implications for investor perception and market engagement.
Leadership
- Gerald, Interim Co-CEO
- Brett Thompson, Chief Technology Officer
Verified email and direct lines for Wellgistics Health’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Wellgistics Health in the news
- Wellgistics Health Completes Reverse Split - Yahoo Finance (May 26, 2026)
- Wellgistics Health Reports Third Quarter 2025 Financial Results and Provides Business Update - Beaver County Times (Nov 20, 2025)
- Wellgistics Targets $70B Market Breakthrough Addressing Ozempic / GLP-1 Muscle Loss with Forzet(TM) - The Coloradoan (Mar 09, 2026)
- Wellgistics Health Announces Launch of Diabetes Drug Brenzavvy(R) to Wellgistics Pharmacy Network - The Star Press (Dec 08, 2025)
- Wellgistics Health Appoints Brian Norton CEO - citybiz (Mar 04, 2025)
- Wellgistics Health (WGRX) Stock Live Price, Chart & News - CoinCodex (Apr 16, 2025)
Companies similar to Wellgistics Health
- Picis Clinical Solutions · Biotechnology, Health Care, Information Technology, Medical
- AKASA · Biotechnology, Health Care, Information Technology, Medical
- Canid · Biotechnology, Health Care, Information Technology, Medical
- Odysight.ai · Biotechnology, Health Care, Information Technology, Medical
- Innventure · Biotechnology, Health Care, Information Technology, Medical
About Wellgistics Health: questions and answers
What does Wellgistics Health do?
Wellgistics Health, Inc. is a leader in next-generation pharmaceutical distribution, digital prescription routing, and AI-powered hub fulfillment. The firm focuses on advancing healthcare technology and solutions for independent pharmacists. With a recent management upgrade, Wellgistics aims to become a force in blockchain-enabled medication tracking. They are enhancing their capabilities to meet
Where is Wellgistics Health headquartered?
Wellgistics Health is headquartered in Tampa, Florida, United States.
How many employees does Wellgistics Health have?
Wellgistics Health has about 51 employees.
Who leads Wellgistics Health?
Gerald is an Interim Co-CEO at Wellgistics Health.
What is the latest news on Wellgistics Health?
On Oct 20, 2026, SEC 8-K (8.01): The filing reports an important event concerning the compliance status of DataMeds AI, Inc. with Nasdaq Listing Rule 5550(b)(1). On October 19, 2026, the Company received written notice from Nasdaq's Listing Qualifications Department confirming that it has regained compliance with th
Is Wellgistics Health a public company?
Yes. Wellgistics Health is publicly traded under the ticker MEDS.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy